<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14777">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02914522</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-418-3898</org_study_id>
    <secondary_id>2016-001392-78</secondary_id>
    <nct_id>NCT02914522</nct_id>
  </id_info>
  <brief_title>Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis</brief_title>
  <official_title>Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the safety and efficacy of filgotinib
      in the induction and maintenance treatment of moderately to severely active ulcerative
      colitis (UC) in participants who are biologic-naive and biologic-experienced.

      Participants who complete the study, or do not meet protocol response or remission criteria
      at Week 10 will have the option to enter a separate, long-term extension (LTE) study (Gilead
      Study GS-US-418-3899).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction Study: Proportion of Participants Achieving Remission Based on Components of Mayo Clinic Score (MCS) at Week 10</measure>
    <time_frame>Week 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintenance Study: Proportion of Participants Achieving Remission Based on Components of MCS at Week 58</measure>
    <time_frame>Week 58</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Induction Study: Proportion of Participants Achieving MCS Remission at Week 10</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Study: Proportion of Participants Achieving Endoscopic Subscore of 0 at Week 10</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Study: Proportion of Participants Achieving Histologic Remission at Week 10</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Study: Proportion of participants achieving MCS remission (alternative definition) at Week 10</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Study: Pharmacokinetic Plasma Concentrations of Filgotinib and its Metabolite GS-829845</measure>
    <time_frame>Week 4 postdose and Week 10 predose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Study: Proportion of Participants Achieving MCS Remission at Week 58</measure>
    <time_frame>Week 58</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Study: Proportion of Participants Achieving Remission Based on Components of MCS at Weeks 10 and 58</measure>
    <time_frame>Weeks 10 and 58</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Study: Proportion of Participants Achieving 6-Month Corticosteroid-Free Remission Based on Components of MCS at Week 58</measure>
    <time_frame>Week 58</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Study: Proportion of Participants Achieving Endoscopic Subscore of 0 at Week 58</measure>
    <time_frame>Weeks 58</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Study: Proportion of Participants Achieving Histologic Remission at Week 58</measure>
    <time_frame>Week 58</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Study: Proportion of participants achieving MCS remission (alternative definition) at Week 58</measure>
    <time_frame>Week 58</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Study: Pharmacokinetic Plasma Concentrations of Filgotinib and its Metabolite GS-829845</measure>
    <time_frame>Week 26 (predose or postdose) and Week 58 predose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Filgotinib Dose A (Induction Study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filgotinib dose A + placebo to match filgotinib dose B for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Filgotinib Dose B (Induction Study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filgotinib dose B + placebo to match filgotinib dose A for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Induction Study)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match dose A + placebo to match dose B for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who meet response or remission criteria at Week 10 will continue into Maintenance Study and will receive filgotinib and/or placebo for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgotinib</intervention_name>
    <description>Tablet(s) administered orally once daily</description>
    <arm_group_label>Filgotinib Dose A (Induction Study)</arm_group_label>
    <arm_group_label>Filgotinib Dose B (Induction Study)</arm_group_label>
    <arm_group_label>Maintenance Study</arm_group_label>
    <other_name>GS-6034</other_name>
    <other_name>GLPG0634</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match filgotinib</intervention_name>
    <description>Tablet(s) administered orally once daily</description>
    <arm_group_label>Filgotinib Dose A (Induction Study)</arm_group_label>
    <arm_group_label>Filgotinib Dose B (Induction Study)</arm_group_label>
    <arm_group_label>Placebo (Induction Study)</arm_group_label>
    <arm_group_label>Maintenance Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Males or non-pregnant, non-lactating females, ages 18 to 75 years, inclusive based on
             the date of the screening visit

          -  Documented diagnosis of UC of at least 6 months AND with a minimum disease extent of
             15 cm from the anal verge. Documentation should include endoscopic and
             histopathologic evidence of UC.

          -  A surveillance colonoscopy is required at screening in individuals with a history of
             UC for 8 or more years, if one was not performed in the prior 24 months

          -  Moderately to severely active UC

          -  Previously demonstrated an inadequate clinical response, loss of response to, or
             intolerance to at least 1 of the following agents: corticosteroids, immunomodulators,
             tumor necrosis factor alpha (TNFa) antagonists, or vedolizumab

        Key Exclusion Criteria:

          -  Presence of Crohn's disease, indeterminate colitis, ischemic colitis, fulminant
             colitis, ulcerative proctitis, or toxic mega-colon

          -  Active tuberculosis (TB) or history of latent TB that has not been treated

          -  Use of any concomitant prohibited medications as described in the protocol

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>418-3898study@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Digestive Health Specialists of the Southeast</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Denver Gastroenterology, PC</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ocean Blue Medical Research Center, Inc</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma CR, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cordova Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Group of Naples</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gulf Region Clinical Research Institute</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research Center</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Central Georgia, LLC</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists of Georgia</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners, LLC</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Louisiana Research Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Clinical Research</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meritus Center for Clinical Research</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21742</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan, LLC</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute, LLC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AGA Clinical Research Associates, LLC</name>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Igor Grosman, DO</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina's GI Research, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Lakes Gastroenterology Research, LLC</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Physicians Centers - Paramount Medical Research &amp; Consulting, LLC</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ClinSearch, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Center of the MidSouth, P.C.</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quality Medical Research, LLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Management, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inquest Clinical Research</name>
      <address>
        <city>Baytown</city>
        <state>Texas</state>
        <zip>77512</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Research of America</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants</name>
      <address>
        <city>San Marcos</city>
        <state>Texas</state>
        <zip>78666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Val R. Hansen, M.D.</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates Of Tidewater</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emeritas Research Group</name>
      <address>
        <city>Leesburg</city>
        <state>Virginia</state>
        <zip>20176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Digestive and Liver Disease Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allegiance Research Specialists, LLC</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Capital and Coast District Health Board</name>
      <address>
        <city>Newton</city>
        <zip>WE 6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H-T. Centrum Medyczne</name>
      <address>
        <city>Tychy</city>
        <zip>43-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Oporow (Medical Centre Oporow)</name>
      <address>
        <city>Wroclaw</city>
        <zip>52-416</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fairfield General Hospital</name>
      <address>
        <city>Bury</city>
        <zip>BL9 7TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G31 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norfold and Norwich University Hospital NHS Foundation Trust</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Whiston Hospital- St Helens And Knowsley Teaching Hospitals NHS Trust</name>
      <address>
        <city>Prescot</city>
        <zip>L35 5DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>September 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Colitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
